Rewards Hub 
Matthew Gallagher is the entrepreneur behind Medvi, a telehealth startup that achieved $401 million in revenue in its first full year of operations — with a team of two people: Gallagher himself and his younger brother Elliot. In 2026, the company is projected to cross $1.8 billion in revenue, making it one of the most remarkable one-person business stories in modern startup history.
If you're searching "Matthew Gallagher," here's everything you need to know about who he is, how he built Medvi, what tools powered his rise, and why his story matters to a generation of entrepreneurs, traders, and founders navigating an AI-first world.
Who Is Matthew Gallagher?
Matthew Gallagher is the founder and CEO of Medvi, a direct-to-consumer telehealth platform specializing in GLP-1 medications — the class of drugs behind the Ozempic and Wegovy weight-loss revolution. He launched the company in September 2024 with just $20,000 in starting capital.
What makes Gallagher's story exceptional isn't the product niche — it's the operational model. From day one, he used AI tools to replace functions that traditionally require dozens of employees: coding (ChatGPT, Claude, Grok), marketing copy, customer service automation, and back-end operations. The result was a company that scaled to unicorn-level revenue without a unicorn-level headcount.
Gallagher's story was covered by Inc., the New York Times, NewsNation, and Hacker News, and quickly became a defining case study for what AI-enabled solopreneurship looks like in practice.
How Did Matthew Gallagher Build Medvi?
Gallagher's approach was not accidental — it was architectural. Rather than hiring to fill roles, he asked a different question: what can AI do instead?
Step 1: Build the product with AI Gallagher used large language models to write the majority of Medvi's codebase. With no traditional engineering team, he iterated on the platform's UX, back-end logic, and telehealth compliance flows using prompts rather than payroll.
Step 2: Automate customer acquisition Marketing copy, email sequences, paid ad creative, and SEO content were all generated and tested with AI assistance. This allowed Gallagher to run multi-channel acquisition campaigns at a fraction of the cost of a traditional growth team.
Step 3: Scale support without headcount Customer service — the traditional bottleneck for telehealth at scale — was handled primarily through AI-powered chat and automated response systems. With 250,000+ customers served, the absence of a large support team would have been impossible before modern LLMs.
Step 4: Stay lean, stay agile By keeping overhead near zero and reinvesting revenue, Medvi grew with a unit economics model most funded startups can't replicate. Gallagher effectively out-executed better-funded competitors by out-automating them.
The Numbers Behind Medvi
| Metric | Figure |
|---|---|
| Founded | September 2024 |
| Starting Capital | $20,000 |
| Team Size | 2 (Matthew + Elliot Gallagher) |
| 2025 Revenue | $401 million |
| 2026 Projected Revenue | $1.8 billion |
| Customers Served | 250,000+ |
| AI Tools Used | ChatGPT, Claude, Grok |
These are numbers that would have been impossible before the LLM era. They represent a structural shift in what a small team can achieve — not incrementally better, but orders-of-magnitude better.
Why Matthew Gallagher's Story Matters Beyond Telehealth
The Medvi story isn't really about GLP-1 drugs. It's about a new operating model for business — one where leverage comes from intelligence stacks, not headcount.
This has implications far beyond healthcare:
For founders: The barrier to building a scalable, revenue-generating company has collapsed. Capital, team size, and execution cycles that once took years now compress into months.
For investors: Traditional valuation frameworks built on team size, TAM, and burn rate need recalibration. A two-person company generating $400M+ in annual revenue breaks nearly every VC heuristic.
For traders: The industries being disrupted by AI-first operators represent major trading opportunities. Telehealth, healthcare SaaS, and insurtech are all sectors where Gallagher's model signals incoming disruption — and where smart capital is repositioning.
The AI + Entrepreneurship Shift: What Traders Should Watch
Matthew Gallagher's Medvi is one data point in a much larger pattern: AI is collapsing the cost of business formation, execution, and scaling. This has several downstream effects worth tracking as a trader:
Healthcare disruption: Traditional telehealth platforms with large headcounts face existential margin pressure from lean AI-native operators.
GLP-1 market dynamics: The underlying drug category — semaglutide, tirzepatide — represents one of the fastest-growing pharmaceutical markets of the decade. Companies in the supply chain (manufacturers, PBMs, specialty pharmacy) are active trading plays.
AI infrastructure demand: Gallagher's reliance on ChatGPT, Claude, and Grok is a microcosm of surging enterprise AI demand — bullish for AI semiconductor and cloud infrastructure stocks.
Macro solopreneurship trend: As more founders build Medvi-style businesses, labor market implications ripple into equities, real estate, and macroeconomic data.
How to Trade the Trends Matthew Gallagher Represents
If Gallagher's story sparks your interest in trading AI-adjacent sectors, Phemex gives you multiple ways to get exposure — without needing a U.S. brokerage account or NYSE access.
Via Crypto: Trade AI-layer tokens and ecosystem coins directly on Phemex spot market and derivatives market.
Via TradFi Perpetuals: Phemex's stock perpetual contracts let you trade price movements of major AI and healthcare-adjacent equities 24/7 — including NVDA, TSLA, AAPL, and more — settled in USDT, with no pattern day trader restrictions.
It's the same philosophy Gallagher applied to Medvi: use the right tools to access opportunities faster than the traditional system allows.
Frequently Asked Questions
Who is Matthew Gallagher? Matthew Gallagher is the founder of Medvi, a telehealth startup that generated $401 million in revenue in 2025 with a two-person team, using AI tools to replace traditional company functions.
What is Medvi? Medvi is a direct-to-consumer telehealth platform specializing in GLP-1 weight-loss medications. It was founded in September 2024 with $20,000 and is projected to reach $1.8 billion in revenue by 2026.
What AI tools does Matthew Gallagher use? Gallagher has publicly credited ChatGPT, Claude, and Grok as the primary AI tools used to build and scale Medvi's operations.
Is Medvi publicly traded? No. Medvi is a private company as of 2026.
What can traders learn from Matthew Gallagher's story? Gallagher's success signals disruption across healthcare, telehealth, and enterprise AI sectors — all of which represent active trading opportunities in both crypto and traditional equity markets.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always conduct your own research before making any investment or trading decision.
